Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. METHODS: In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days (range, 30 to 42). The main secondary efficacy outcome was major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism). The primary safety outcome was major bleeding. RESULTS: A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 2.6%; 95% confidence interval [CI], 1.5 to 3.7; P<0.001). Major venous thromboembolism occurred in 4 of 1686 patients (0.2%) in the rivaroxaban group and in 33 of 1678 patients (2.0%) in the enoxaparin group (absolute risk reduction, 1.7%; 95% CI, 1.0 to 2.5; P<0.001). Major bleeding occurred in 6 of 2209 patients (0.3%) in the rivaroxaban group and in 2 of 2224 patients (0.1%) in the enoxaparin group (P=0.18). CONCLUSIONS: A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationThe Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Self-citationRoentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Self-citationRosencher, N., Kerkkamp, H. E. M., Macheras, G., Munuera, L. M., Menichella, G., Barton, D. M., Cremers, S., Abraham, I. L., & Investigation, F. T. O. (2003) · Transfusion · doi:10.1046/j.1537-2995.2003.00348.x · Cited by 603
Eikelboom, J. W., Quinlan, D. J., & Douketis, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05249-1 · Cited by 513
Research works printed but not linked: 1
- 10.1016/s0140-6736(07)61445-7 · DOI · Paper page
Cited by
Items 301–400 of 1,000
Hamidi, M., Zeeshan, M., Kulvatunyou, N., Mitra, H. S., Hanna, K., Tang, A. L., Northcutt, A., O’Keeffe, T., & Joseph, B. A. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14439 · Cited by 44
Gao, F., SUN, W. M., Guo, W., Li, Z., Wang, W., & Cheng, L. (2015) · The Journal of Arthroplasty · doi:10.1016/j.arth.2015.06.005 · Cited by 40
“Extensive blood loss after THA is often associated with cardiovascular complications and a high rate of allogeneic blood transfusion (ABT) [4,7], and about half of the patients with total joint arthroplasty have received more than 2 U of blood postoperatively [8,9].”
BackgroundRosencher, N., Llau, J. V., Mueck, W., LOEWE, A., Berkowitz, S. D., & Homering, M. (2013) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12069 · Cited by 37
Ren, Y., Cao, S.-L., Li, Z., Luo, T., Feng, B., & Weng, X. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001305 · Cited by 39
“Colwell et al[28] adopted a compression device with a lower dose, 81 mg per day, to compare its safety and efficacy with LMWH after total hip replacement, suggesting that a lower incidence of major bleeding but equal VTE risk under aspirin-combined therapy.”
BackgroundResultInfluentialTsantes, A. G., Papadopoulos, D. V., Trikoupis, I. G., Tsante, K. A., Mavrogenis, A. F., Koulouvaris, P., Piovani, D., Kriebardis, A. G., Gialeraki, A. E., Nikolopoulos, G. K., et al. (2021) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000001832 · Cited by 36
Recommendations from the ICM-VTE: General
Delegates, T. I.-V. G. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.21.01531 · Cited by 38
Caldeira, D., Canastro, M., Barra, M., Ferreira, A., Costa, J. N., Pinto, F. J., & Ferreira, J. J. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.0985 · Cited by 39
Cohen, A. T., & the Asia-Pacific Thrombosis Advisory Board (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-03-0190 · Cited by 39
“1998 (95) THR Dextran Venography 3/50 (6) 10/50 (20)”
Kaeberich, A., Reindl, I., Raaz, U., Mäegdefessel, L., Vogt, A., Linde, T., Steinseifer, U., Perzborn, E., Hauroeder, B., Buerke, M., et al. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0621-6 · Cited by 38
Rivaroxaban for Venous Thromboembolism Prophylaxis in Abdominoplasty: A Multicenter Experience
Hunstad, J. P., Krochmal, D. J., Flugstad, N. A., Kortesis, B. G., Augenstein, A. C., & Culbertson, G. R. (2015) · Aesthetic Surgery Journal · doi:10.1093/asj/sjv117 · Cited by 37
“(initial FDA indications), and bleeding rates were found to be similar to enoxaparin.(21,22) Regarding cost compared with enoxaparin, rivaroxaban demonstrated a cost savings in patients with total hip and total knee replacements.”
BackgroundYhim, H., Lee, J., Lee, J. Y., Lee, J., & Bang, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178214 · Cited by 38
Lü, X., & Jin, L. (2018) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-018-2215-3 · Cited by 44
Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal
Stevenson, M., Scope, A., Holmes, M., Rees, A., & Kaltenthaler, E. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl3/07 · Cited by 37
New and Emerging Anticoagulant Therapy for Atrial Fibrillation and Acute Coronary Syndrome
Davis, E. M., Packard, K. A., Knezevich, J. T., & Campbell, J. A. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.10.975 · Cited by 35
Turun, S., Banghua, L., Yuan, Y., Zhenhui, L., Ying, N., & Chen, J. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.01.016 · Cited by 39
“All the eight studies included were RCTs [29–36] (Table 1); six studies compared rivaroxaban with 40 mg enoxaparin daily, two compared rivaroxaban with 30 mg enoxaparin daily, five investigated short-term therapy with rivaroxaban, and three examined extended therapy with rivaroxaban.”
BackgroundLevitan, B. S., Yuan, Ž., Turpie, A. G. G., Friedman, R. J., Homering, M., Berlin, J. A., Berkowitz, S. D., Weinstein, R. B., & DiBattiste, P. M. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s54714 · Cited by 37
Self-citationSindali, K., Rose, B., Soueid, H., Jeer, P. J. S., Saran, D., & Shrivastava, R. (2012) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-012-0987-y · Cited by 41
Saragas, N. P., & Ferrao, P. N. F. (2011) · Foot and Ankle Surgery · doi:10.1016/j.fas.2010.12.002 · Cited by 35
Cohen, A. T., Imfeld, S., Markham, J., & Granziera, S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.036 · Cited by 38
“These studies have demonstrated reductions in VTE risk of up to 70% compared with standard of care, without significant increases in the risk of major bleeding [33–40,45,46].”
BackgroundMethodResultInfluentialCabral, K. P., Ansell, J., & Hylek, E. M. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04179.x · Cited by 39
Escolar, G., Arellano‐Rodrigo, E., López-Vílchez, I., Molina, P., Sanchis, J., Reverter, J. C., Carné, X., Cid, J., Villalta, J., Tàssies, D., et al. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0909 · Cited by 37
“Whole blood samples spiked with rivaroxaban were used to evaluate modifications in: (1) viscoelastic parameters of clot formation in whole blood using thromboelastometry (ROTEM, TEM International GmbH, Munchen, Germany); (2) dynamics of thrombin generation (TG) in plasma using the fluorogenic assay, Technothrombin TGA…”
MethodThe Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations
Caterina, R. D., Ageno, W., Agnelli, G., Chan, N., Diener, H., Hylek, E. M., Raskob, G. E., Siegal, D. M., Verheugt, F. W. A., Lip, G. Y. H., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1675816 · Cited by 37
A role for coagulation factor Xa in experimental pulmonary arterial hypertension
Delbeck, M., Nickel, K., Perzborn, E., Ellinghaus, P., Straßburger, J., Kast, R., Laux, V., Schäfer, S., SCHERMULY, R. T., & von Degenfeld, G. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr168 · Cited by 36
Developments in factor Xa inhibitors for the treatment of thromboembolic disorders
Lee, Y., & Player, M. R. (2011) · Medicinal Research Reviews · doi:10.1002/med.20183 · Cited by 39
Wangge, G., Roes, K. C. B., de Boer, A., Hoes, A. W., & Knol, M. J. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.120142 · Cited by 34
The discovery and development of rivaroxaban
Misselwitz, F., Berkowitz, S. D., & Perzborn, E. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05971.x · Cited by 38
Self-citationMerli, G. J., Spyropoulos, A. C., & Caprini, J. A. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181ae6dbe · Cited by 36
“An unexpected increase in these acute coronary syndrome events was previously observed with ximelagatran.(23)”
BackgroundResultPreventing Postsurgical Venous Thromboembolism: Pharmacological Approaches
Tufano, A., Coppola, A., Cerbone, A. M., Ruosi, C., & Franchini, M. (2011) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0031-1273089 · Cited by 34
Fatal pulmonary embolism following elective total hip arthroplasty: a 12-year study
Bayley, E. J., Brown, S., Bhamber, N., & Howard, P. W. (2016) · The Bone & Joint Journal · doi:10.1302/0301-620x.98b5.34996 · Cited by 39
Khoo, C. W., Tay, K.-H., Shantsila, E., & Lip, G. Y. H. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02011.x · Cited by 35
Oh, H. J., Ryu, K. H., Park, B. J., & Yoon, B. (2021) · Medicine · doi:10.1097/md.0000000000025216 · Cited by 34
Lee, F. M. H., Chan, A. K. C., Lau, K. K., & Chan, H. H. W. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.01.031 · Cited by 37
Mahmoudi, M., & Sobieraj, D. M. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1269 · Cited by 34
Long, A., Zhang, L., Zhang, Y., Jiang, B., Mao, Z., Li, H., Zhang, S., Xie, Z., & Tang, P. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-1046-1 · Cited by 38
Factor Xa inhibitors: New anticoagulants for secondary haemostasis
Perzborn, E. (2009) · Hämostaseologie · doi:10.1055/s-0037-1617033 · Cited by 35
“1 Incidence of venous thromboembolism and bleeding events across the four RECORD studies (11, 24, 29, 46)”
BackgroundRivaroxaban for thrombosis prophylaxis in endovenous laser ablation with and without phlebectomy
Uthoff, H., Holtz, D. J., Brož, P., Staub, D., & Spinedi, L. (2017) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2016.12.002 · Cited by 35
Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations
Elhosseiny, S., Moussawi, H. A., Chalhoub, J. M., Lafferty, J., & Deeb, L. S. (2019) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2019/4383269 · Cited by 33
“All reported cases of liver injury recovered after stopping Rivaroxaban [3, 55].”
BackgroundSafety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism
Giustozzi, M., Franco, L., Vedovati, M. C., Becattini, C., & Agnelli, G. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01878-x · Cited by 38
Hernandez, C. M. R., & Garcia, D. A. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1333536 · Cited by 34
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Ma, T. K. W., Yan, B. P., & Lam, Y. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.09.005 · Cited by 32
A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban
Kreutz, R. H. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-1029-2 · Cited by 32
“Consequently, a once-daily rivaroxaban 10 mg regimen was evaluated in the phase III RECORD clinical trial program [63–66].”
BackgroundMethodInfluentialNewer Anticoagulants in Cardiovascular Disease: A Systematic Review of the Literature
Maan, A., Padmanabhan, R., Shaikh, A. Y., Mansour, M., Ruskin, J. N., & Heist, E. K. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e3182503e2d · Cited by 36
Regional anaesthesia and anticoagulation
Vandermeulen, E. (2010) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2009.09.004 · Cited by 36
Green, L., Lawrie, A. S., Patel, S., Hossain, F. S., Chitolie, A., Mackie, I. J., Haddad, F. S., & Machin, S. J. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08433.x · Cited by 33
“…also support the results of the four phase III clinical trials (RECORD [Regulation of Coagulation in Orthopaedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism) 1–4] which involved >12 500 patients (Eriksson et al, 2008; Kakkar et al, 2008; Lassen et al, 2008; Turpie et al, 2009).”
BackgroundResultHaykal, T., Kheiri, B., Zayed, Y., Barbarawi, M., Miran, M. S., Chahine, A., Katato, K., & Bachuwa, G. I. (2019) · Journal of Orthopaedics · doi:10.1016/j.jor.2019.03.003 · Cited by 33
RetractedStevenson, J. W., Minns, A. B., Smollin, C. G., Albertson, T. E., Cantrell, F. L., Tomaszewski, C., & Clark, R. F. (2014) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2014.04.031 · Cited by 32
Gheorghiade, M., Thyssen, A., Zolynas, R., Nadar, V., Greenberg, B., Mehra, M. R., Sun, X., Tian, H., Plotnikov, A. N., & Burton, P. B. J. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.08.027 · Cited by 34
Ryttberg, L., Diamantopoulos, A., Forster, F., Lees, M., Fraschke, A., & Björholt, I. (2011) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.11.65 · Cited by 32
Chan, N., Stehouwer, A. C., Hirsh, J., Ginsberg, J. S., Alazzoni, A., Coppens, M., Guyatt, G. H., & Eikelboom, J. W. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1006 · Cited by 37
Pina, L. M., Dong, X., Zhang, L., Samtani, M. N., Michelson, A. D., Justino, H., Bonnet, D., Harris, K. C., Jefferies, J. L., McCrindle, B. W., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.04.009 · Cited by 34
Reversal of New Oral Anticoagulants
Battinelli, E. M. (2011) · Circulation · doi:10.1161/circulationaha.111.054510 · Cited by 36
Lewis, S., Glen, J., Dawoud, D., Dias, S., Cobb, J. K., Griffin, X. L., Reed, M., Sharpin, C., Stansby, G. P., & Barry, P. (2019) · Value in Health · doi:10.1016/j.jval.2019.02.013 · Cited by 31
Eriksson, B. I., Rosencher, N., Friedman, R. J., Homering, M., & Dahl, O. E. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2011.12.005 · Cited by 33
Self-citationPractical issues, limitations, and periprocedural management of the NOAC’s
Connolly, G. C., & Spyropoulos, A. C. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0911-2 · Cited by 33
Moving Toward a More Ideal Anticoagulant
King, C. S., Holley, A. B., & Moores, L. K. (2013) · CHEST Journal · doi:10.1378/chest.12-1362 · Cited by 32
Direct oral anticoagulants: An update
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.07.005 · Cited by 34
Douillet, D., Chapelle, C., Ollier, É., Mismetti, P., Roy, P., & Laporte, S. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004059 · Cited by 32
Prevention of VTE in patients having major orthopedic surgery
Francis, C. W. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0889-9 · Cited by 34
“daily starting 6–8 h after surgery and continued once daily compared with standard regimens of enoxaparin [23–26].”
MethodMao, L., Li, C., Li, T., & Yuan, K. (2013) · Vascular · doi:10.1177/1708538113490423 · Cited by 32
Caldeira, D., Gonçalves, N., Pinto, F. J., Costa, J. N., & Ferreira, J. J. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3791 · Cited by 31
The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure
Flierl, U., Fraccarollo, D., Micka, J., Bauersachs, J. K., & Schäfer, A. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.05.002 · Cited by 32
New anticoagulants: A concise review
Kreuziger, L. B., Morton, C. T., & Dries, D. J. (2012) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e318265cf9e · Cited by 31
Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence
Bracey, A., Shatila, W., & Wilson, J. M. (2018) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944718801554 · Cited by 31
Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review
Ajmal, M., Friedman, J., Sipra, Q. U. A. R., & Lassar, T. A. (2021) · Cardiovascular Therapeutics · doi:10.1155/2021/8886210 · Cited by 34
Kubitza, D., Becka, M., Schwers, S., & Voith, B. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.26 · Cited by 30
Assessment of Patient Adherence to Direct Oral Anticoagulant vs Warfarin Therapy
Patel, S. I., Cherington, C. C., Scherber, R. M., Barr, K., McLemore, R. Y., Morisky, D. E., Cha, S., Mookadam, F., & Shamoun, F. E. (2017) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2017.002 · Cited by 31
Thiel, D. H. V., Kalodiki, E., Wahi, R., Litinas, E., Haque, W., & Rao, G. H. R. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029609340163 · Cited by 32
New anticoagulants for the prevention of venous thromboembolism
Becattini, C., Lignani, & Agnelli (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6074 · Cited by 31
Randelli, F., Biggi, F., Rocca, C. D., Grossi, P., Imberti, D., Landolfi, R., Palareti, G., & Prisco, D. (2011) · Journal of Orthopaedics and Traumatology · doi:10.1007/s10195-010-0125-8 · Cited by 29
Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change
Zikria, J., & Ansell, J. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32832ea2d7 · Cited by 31
Cove, C. L., & Hylek, E. M. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000136 · Cited by 33
The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations
Ashton, V., Kerolus‐Georgi, S., & Moore, K. T. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1838 · Cited by 34
Amarase, C., Tanavalee, A., Larbpaiboonpong, V., Lee, M. C., Crawford, R., Matsubara, M., Zhou, Y., Asia-Pacific (AP) Region Venous Thromboembolism (VTE) Consensus Group, Unnanuntana, A., Tan, A., et al. (2021) · Knee Surgery and Related Research · doi:10.1186/s43019-021-00101-7 · Cited by 31
Kinov, P. S., Tanchev, P. P., Ellis, M. H., & Volpin, G. (2013) · International Orthopaedics · doi:10.1007/s00264-013-2134-8 · Cited by 33
“039) [40–43].”
Venous thromboembolism: risks and prevention
Barker, R. C., & Marval, P. (2010) · Continuing Education in Anaesthesia Critical Care & Pain · doi:10.1093/bjaceaccp/mkq044 · Cited by 34
Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty
Charters, M. A., Frisch, N. B., Wessell, N. M., Dobson, C. E., Les, C. M., & Silverton, C. D. (2015) · The Journal of Arthroplasty · doi:10.1016/j.arth.2015.02.009 · Cited by 31
“7% [2–5].”
BackgroundInfluentialWang, C., Yang, F., Xu, Z., Shi, D., Chen, D., Dai, J., Gu, N., & Jiang, Q. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2012.11.002 · Cited by 28
Practical aspects of the oral new anticoagulants
DeLoughery, T. G. (2011) · American Journal of Hematology · doi:10.1002/ajh.22021 · Cited by 29
“In a study in total knee arthroplasty (TKA), when compared to enoxaparin 30-mg bid, dabigatran at 150 and 220 mg daily was inferior due to a greater number of distal thromboses (220—27.6%, 150—30.5%, and enoxaparin 23.0”
BackgroundMethodInfluentialA case report describing a suspected rivaroxaban hypersensitivity reaction in a surgical patient
Yates, J., Choudhry, M., & Keys, G. W. (2012) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12013 · Cited by 28
Treatment with novel oral anticoagulants: indications, efficacy and risks
Ghanny, S., & Crowther, M. A. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328363c170 · Cited by 32
“In ADVANCE-3, apixaban was more effective than prophylaxis with enoxaparin following elective hip replacement (THJR) without increased bleeding [7].”
ResultInfluentialKwong, L. M. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4441 · Cited by 30
Fesler, M. J., Creer, M. H., Richart, J. M., Edgell, R. C., Havlioglu, N., Norfleet, G., & Cruz‐Flores, S. (2010) · Neurocritical Care · doi:10.1007/s12028-009-9320-y · Cited by 28
“Dabigatran, a direct thrombin inhibitor, and rivaroxaban, a direct factor Xa inhibitor, are two oral anticoagulants that do not cause HIT, and have demonstrated a promising safety and efficacy profile for treatment and prevention of various hypercoaguable states [20, 21].”
BackgroundIdestrup, C., Sawhney, M., Nix, C. M., & Kiss, A. (2014) · Regional Anesthesia & Pain Medicine · doi:10.1097/aap.0000000000000127 · Cited by 30
“Rivaroxaban has been shown to be superior to enoxaparin for thromboprophylaxis following THA and TKAwhile having a similar safety profile with regard to the rate of major bleeding events.(7,8) The analgesia regimen for patients undergoing TKA at the Holland Orthopaedic and Arthritic Centre consists of multimodal analg…”
BackgroundThe use of rivaroxaban for short- and long-term treatment of venous thromboembolism
Cohen, A. T., & Dobromirski, M. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-12-0859 · Cited by 32
Pedersen, A. B., Sørensen, H. T., Mehnert, F., Johnsen, S. P., & Overgaard, S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.029 · Cited by 29
“In general, trials include healthier and younger participants than average THR patients [36], and they are usually conducted in highly controlled and monitored settings.”
BackgroundEmergence of new oral antithrombotics: a critical appraisal of their clinical potential
Laux, V. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3266 · Cited by 34
“Proof of concept was demonstrated in a phase IIa dose-escalation study to assess the effi cacy and safety of YM150 for VTE prevention after THR (Eriksson et al 2007b).”
InfluentialPathology Consultation on Anticoagulation Monitoring
Wool, G. D., & Lu, C. M. (2013) · American Journal of Clinical Pathology · doi:10.1309/ajcpr3jtok7nkdbj · Cited by 28
Perka, C. (2011) · Thrombosis Journal · doi:10.1186/1477-9560-9-17 · Cited by 30
“While postoperative initiation was effective, a major limitation to evaluating the comparative safety of rivaroxaban is the unique bleeding definition used in the studies [22-24].”
BackgroundMethodInfluentialCurrent State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors
Nitzki‐George, D., Wozniak, I., & Caprini, J. A. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r724 · Cited by 27
Agarwal, A. R., Das, A., Harris, A. B., Campbell, J. C., Golladay, G. J., & Thakkar, S. C. (2023) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-22-00708 · Cited by 27
Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty
Piple, A. S., Wang, J. C., Kang, H. P., Mills, E. S., Mayfield, C. K., Lieberman, J. R., Christ, A. B., & Heckmann, N. D. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.02.028 · Cited by 28
Gómez‐Outes, A., Suárez-Gea, Lecumberri, R., Terleira‐Fernández, A. I., Vargas, E., & Rocha (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s35843 · Cited by 28
Massive human rivaroxaban overdose
Lehmann, T., Hofer, K. E., Baumann, M., Hasler, K., Ceschi, A., Kupferschmidt, H., Rohde, G., & Korte, W. C. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-02-0138 · Cited by 27
Llau, J. V., Ferrandis, R., Castillo, J., de Andrés, J., Gomar, C. G., Gómez‐Luque, A., Hidalgo, F., & Torres, L. M. (2012) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2012.01.007 · Cited by 32
Succinct Review of the New VTE Prevention and Management Guidelines
Pollak, A. W., & McBane, R. D. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.015 · Cited by 28
Ricket, A. L., Stewart, D. W., Wood, R. C., Cornett, L., Odle, B. L., Cluck, D. B., Freshour, J. E., & El‐Bazouni, H. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028015626435 · Cited by 30
Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Ravikumar, R., Williams, K. J., Babber, A., Moore, H. M., Lane, T. R. A., Shalhoub, J., & Davies, A. H. (2017) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355517710130 · Cited by 28
Fifty years of research on antithrombotic therapy: Achievements and disappointments
Hirsh, J., Eikelboom, J. W., & Chan, N. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.10.023 · Cited by 29
Nederpelt, C. J., Breen, K., Hechi, M. W. E., Krijnen, P., Huisman, M. V., Schipper, I. B., Kaafarani, H. M. A., & Rosenthal, M. D. (2020) · Journal of Surgical Research · doi:10.1016/j.jss.2020.10.009 · Cited by 27
Self-citationAquilina, A. L., Brunton, L. R., Whitehouse, M. R., Sullivan, N., & Blom, A. W. (2012) · Hip International · doi:10.5301/hip.2012.9058 · Cited by 29
Metadata
- Authors
- Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., & Geerts, W.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Aarhus University Hospital (DK)
- Medical University of South Carolina (US)
- Technical University of Munich (DE)
- Leiden University Medical Center (NL)
- Queen Mary University of London (GB)
- Bayer (Germany) (DE)
- University of Toronto (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-06-26
- Volume
- 358
- Issue
- 26
- Pages
- 2765-2775
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2014491911
- Cited by
- 1,433
- References
- 25
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 24 · 2023: 35 · 2022: 39 · 2021: 55 · 2020: 47 · 2019: 47 · 2018: 60 · 2017: 68 · 2016: 86 · 2015: 92 · 2014: 98 · 2013: 167 · 2012: 159
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, venous thromboembolism, deep vein thrombosis, pulmonary embolism, factor Xa inhibitors, major bleeding, postoperative anticoagulation
- MeSH terms
- Rivaroxaban, Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thrombosis, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.